Getting TRD Patients to Remission Faster in 2026

What the Research Says

A new analysis published in Psychiatric Times highlights a persistent gap in depression care: many patients with treatment-resistant depression (TRD) spend months — or years — cycling through medications without reaching remission, not always because better options don't exist, but because those options aren't being used as effectively as they could be.

The piece focuses on a cluster of evidence-backed clinical practices that, when combined, meaningfully shorten the path to remission. These include measurement-based care (using validated symptom scales at every visit rather than relying on clinical intuition alone), proactive dose optimization (moving quickly when a treatment isn't working rather than waiting out arbitrary timelines), and systematic management of side effects that cause patients to abandon treatments prematurely.

The "more efficacious treatments" the title references include newer interventions like esketamine nasal spray (Spravato) and, by extension, the broader family of ketamine-based therapies that have become a meaningful part of TRD care over the past decade. The underlying argument is straightforward: even the best treatments underperform when clinicians don't monitor response closely, adjust doses in real time, or address the tolerability issues that push patients off course.

Why This Matters for Ketamine Patients

For anyone evaluating ketamine as a treatment for depression — whether IV infusion, intramuscular injection, intranasal esketamine, or oral and sublingual formulations — this article speaks directly to something that often gets overlooked in conversations about efficacy: the quality of clinical management matters as much as the treatment itself.

Ketamine's speed advantage over traditional antidepressants is one of its most frequently cited benefits. Where SSRIs and SNRIs may take four to six weeks to show meaningful effects, ketamine can produce antidepressant responses within hours to days. But that speed advantage is only fully realized when providers are actively tracking response, communicating with patients between sessions, and making adjustments — whether to dosing, infusion frequency, or adjunctive medications — based on real data rather than fixed protocols.

The research on measurement-based care in TRD is consistent: patients whose providers use standardized symptom tools (like the PHQ-9, MADRS, or QIDS) at regular intervals do better than those in practices relying on unstructured check-ins. For ketamine patients, this means the difference between a provider who asks "how are you feeling?" and one who scores your symptoms before and after each session, tracks trends over time, and uses that data to guide your course of treatment.

Side effect management is equally relevant. Ketamine's dissociative effects, while generally transient and well-tolerated, can be distressing for some patients — particularly early in treatment. Clinics that monitor these experiences systematically, adjust infusion rates, or use anxiolytic pre-medications appropriately are doing exactly what this research recommends: removing tolerability barriers that would otherwise cause patients to stop treatment before reaching remission.

What to Look for When Choosing a Provider

This research gives patients and their families a practical lens for evaluating ketamine clinics and providers. Not all practices approach TRD with the same rigor, and the difference often lies in the infrastructure surrounding the treatment, not just the treatment itself.

Questions worth asking a prospective provider include: Do you use a standardized depression scale to track my progress at each visit? How do you determine whether my dosing needs to change? What is your protocol if I am not responding after a set number of sessions? How do you manage dissociation or anxiety during infusions?

Providers who can answer these questions specifically — ideally by referencing their clinical protocols — are more likely to be practicing the kind of adaptive, measurement-based care the evidence supports. Those who rely primarily on subjective impressions and fixed-dose protocols may be less equipped to optimize your outcome.

Route of administration also shapes how this optimization plays out in practice. IV ketamine, administered in a clinical setting, offers the most direct opportunity for real-time monitoring and dose adjustment during the infusion itself. Intranasal esketamine (Spravato), delivered in certified healthcare settings under observation, similarly enables structured response tracking. At-home oral or sublingual ketamine — increasingly common through telehealth platforms — places more of the monitoring responsibility on the patient and makes the quality of between-session follow-up especially critical.

That doesn't mean at-home formats are categorically less effective, but it does mean the clinical touchpoints around the treatment need to be even more intentional when a provider isn't present during administration. The core lesson from this Psychiatric Times analysis applies regardless of format: structured measurement, responsive adjustment, and proactive side effect management are what convert a promising treatment into a reliable path to remission.